SB-728-T

SB-728-T is an investigational gene therapy product developed to treat HIV infection. It consists of autologous CD4 T cells that have been genetically modified ex vivo using zinc finger nucleases (ZFNs) delivered via adenovirus vector or mRNA to disrupt the CCR5 gene. The targeted disruption of the CCR5 gene prevents expression of the C-C chemokine receptor type 5 (CCR5) receptor on CD4 cells—a key co-receptor required for HIV entry—rendering these cells resistant to infection by the most common strain of HIV. This approach is inspired by individuals with a natural homozygous CCR5-delta32 mutation who are highly resistant to HIV infection. The therapy aims to provide patients with a durable pool of immune cells that are less susceptible or resistant to HIV, potentially improving immune restoration and offering functional control over the virus[1][2][3][4][6].

Other names

CD4 CAR+ ZFN-modified T CellsAutologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIVZFN Modified CD4+T cells